惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

J
Java Code Geeks
腾讯CDC
Jina AI
Jina AI
博客园 - 司徒正美
博客园 - 三生石上(FineUI控件)
Apple Machine Learning Research
Apple Machine Learning Research
GbyAI
GbyAI
WordPress大学
WordPress大学
Hugging Face - Blog
Hugging Face - Blog
T
The Blog of Author Tim Ferriss
小众软件
小众软件
M
MIT News - Artificial intelligence
MyScale Blog
MyScale Blog
D
Docker
H
Hackread – Cybersecurity News, Data Breaches, AI and More
Google DeepMind News
Google DeepMind News
月光博客
月光博客
L
LangChain Blog
F
Fortinet All Blogs
Microsoft Azure Blog
Microsoft Azure Blog
博客园 - Franky
C
Check Point Blog
U
Unit 42
人人都是产品经理
人人都是产品经理

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
2026-05-09 · via All Articles on Seeking Alpha

Q1: 2026-05-07 Earnings Summary

EPS of -$0.29 misses by $0.00

 | 

Revenue of

$15.47M

(-24.91% Y/Y)

beats by $370.00K

Personalis, Inc. (PSNL) Q1 2026 Earnings Call May 7, 2026 5:00 PM EDT

Company Participants

Christopher Hall - CEO & Director
Aaron Tachibana - CFO & COO
Richard Chen - Executive VP of R&D, President & Chief Medical Officer

Conference Call Participants

Caroline Corner - Westwicke Partners, LLC
Subbu Nambi
Mark Massaro - BTIG, LLC, Research Division
Thomas Flaten - Lake Street Capital Markets, LLC, Research Division
Joseph Conway - Needham & Company, LLC, Research Division
Daniel Brennan
William Bonello - Craig-Hallum Capital Group LLC, Research Division

Presentation

Operator

Greetings, and welcome to the Personalis First Quarter 2026 Earnings Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded.

It is now my pleasure to introduce Caroline Corner of Investor Relations. Thank you, and you may proceed, Caroline.

Caroline Corner
Westwicke Partners, LLC

Thank you, operator. Welcome to Personalis' First Quarter 2026 Earnings Call. Joining today's call are Chris Hall, Chief Executive Officer; Aaron Tachibana, Chief Financial and Chief Operating Officer; and Rich Chen, President and Chief Medical Officer.

All statements made on this call that do not relate to matters of historical facts should be considered forward-looking statements within the meaning of the U.S. securities laws, including any statements regarding trends and expectations for our financial performance this year and longer term, cash runway and liquidity position, revenue expectations and timing, size and booking of orders, products, services, technology, expansion of clinical volume, reimbursement goals, the outcome and timing of reimbursement decisions, expectations for our existing and future collaboration activities, cost expectations, market size and our market opportunity and business outlook.

These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. We encourage you to review our recent filings, including the risk factors described in our most recent filings. Personalis undertakes no obligation to update these